Alex Fotopoulos
Directeur Technique/Scientifique/R&D chez PASSAGE BIO, INC.
Fortune : 96 005 $ au 30/04/2024
Postes actifs de Alex Fotopoulos
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PASSAGE BIO, INC. | Directeur Technique/Scientifique/R&D | 01/07/2019 | - |
Historique de carrière de Alex Fotopoulos
Anciens postes connus de Alex Fotopoulos
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Directeur Technique/Scientifique/R&D | 01/11/2017 | 01/07/2019 |
| DIMENSION THERAPEUTICS INC | Directeur Technique/Scientifique/R&D | 01/05/2016 | 01/11/2017 |
| MOMENTA PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/08/2011 | 01/05/2016 |
| BIOGEN INC. | Corporate Officer/Principal | 01/08/1994 | 01/01/2011 |
Formation de Alex Fotopoulos
| Tufts University | Graduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PASSAGE BIO, INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Dimension Therapeutics, Inc.
 Dimension Therapeutics, Inc. BiotechnologyHealth Technology Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz in June 20, 2013 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Alex Fotopoulos
- Expérience
